Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth

Neoplasia

Volumn 8, Issue 5, 2006, Pages 419-428

  Lee, Ok Hee ^a   Fueyo, Juan ^a   Xu, Jing ^a   Yung, W K Alfred ^a   Lemoine, Michael G ^a   Lang, Frederick F ^a   Bekele, B Nebiyou ^a   Zhou, Xian ^a   Alonso, Marta A ^a   Aldape, Kenneth D ^a   Fuller, Gregory N ^a   Gomez Manzano, Candelaria ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiopoietin 2; Animal model; Glioma; Tumor growth; Vascular development

Indexed keywords

ADENOVIRUS VECTOR; ANGIOPOIETIN 2; COMPLEMENTARY DNA;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL INJURY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CHORIOALLANTOIS; CONTROLLED STUDY; FEMALE; GLIOMA CELL; HUMAN; HUMAN CELL; KINETICS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR NECROSIS; VASCULARIZATION; XENOGRAFT;

EID: 33744829739     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06109     Document Type: Article

References (30)

1. Levin VA, Gutin PH, and Leivel S (1997). Neoplasms of the central nervous system. In Cancer. Principles and Practice of Oncology (5th ed). DeVita VT, Hellman SJ, Rosenberg SA, (Eds). Philadelphia, PA, pp. 2022-2072.
2. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, and DePinho RA (2001). Malignant glioma: genetics and biology of a grave matter. Genes Dev 15, 1311-1333.
3. Hanahan D and Folkman J (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364.
4. Hlatky L, Hahnfeldt P, and Folkman J (2002). Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94, 883-893.
5. Weidner N, Semple JP, Welch WR, and Folkman J (1991). Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324, 1-8.
6. Bergers G, Javaherian K, Lo KM, Folkman J, and Hanahan D (1999). Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812.
7. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, and Wiegand SJ (1999). Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994-1998.
8. Zagzag D, Amirnovin R, Greco MA, Yee H, Holash J, Wiegand SJ, Zabski S, Yancopoulos GD, and Grumet M (2000). Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 80, 837-849.
9. D'Angelo MG, Afanasieva DA, and Aguzzi T (2000). Angiogenesis in transgenic models of multistep carcinogenesis. J Neuro-Oncol 50, 89-98.
10. Bergers G and Benjamin LE (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3, 401-410.
11. Goldbrunner RH, Wagner S, Roosen K, and Tonn JC (2000). Models for assessment of angiogenesis in gliomas. J Neuro-Oncol 50, 53-62.
12. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, et al. (1997). Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277, 55-60.
13. Goede V, Schmidt T, Kimmina S, Kozian D, and Augustin HG (1998). Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 78, 1385-1394.
14. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte MH, Jackson D, et al. (2002). Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 3, 411-423.
15. Hu B, Guo P, Fang Q, Tao HQ, Wang D, Nagane M, Huang HJ, Gunji Y, Nishikawa R, Alitalo K, et al. (2003). Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci USA 100, 8904-8909.
16. Machein MR, Knedla A, Knoth R, Wagner S, Neuschl E, and Plate KH (2004). Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model. Am J Pathol 165, 1557-1570.
17. Lal S, Lacroix M, Tofilon P, Fuller GN, Sawaya R, and Lang FF (2000). An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg 92, 326-333.
18. Attia MA and Weiss DW (1966). Immunology of spontaneous mammary carcinomas in mice: V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. Cancer Res 26, 1787-1800.
19. Im SA, Kim JS, Gomez-Manzano C, Fueyo J, Liu TJ, Cho MS, Seong CM, Lee SN, Hong YK, and Yung WK (2001). Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF. Br J Cancer 84, 1252-1257.
20. Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, Bruner JM, Chintala SK, Rao JS, Levin VA, and Kyritsis AP (1998). Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology 50, 1307-1315.
21. Gomez-Manzano C, Fueyo J, Kyritsis AP, McDonnell TJ, Steck PA, Levin VA, and Yung WK (1997). Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst 89, 1036-1044.
22. Brooks PC, Montgomery AM, and Cheresh DA (1999). Use of the 10-day-old chick embryo model for studying angiogenesis. Methods Mol Biol 129, 257-269.
23. Sugawara K, Kurihara H, Negishi M, Saito N, Nakazato Y, Sasaki T, and Takeuchi T (2002). Nestin as a marker for proliferative endothelium in gliomas. Lab Invest 82, 345-351.
24. Zagzag D, Hooper A, Friedlander DR, Chan W, Holash J, Wiegand SJ, Yancopoulos GD, and Grumet M (1999). In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 159, 391-400.
25. Stratmann A, Risau W, and Plate KH (1998). Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153, 1459-1466.
26. Nagano N, Sasaki H, Aoyagi M, and Hirakawa K (1993). Invasion of experimental rat brain tumor: early morphological changes following microinjection of C6 glioma cells. Acta Neuropathol (Berl) 86, 117-125.
27. Koga K, Todaka T, Morioka M, Hamada J, Kai Y, Yano S, Okamura A, Takakura N, Suda T, and Ushio Y (2001). Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 61, 6248-6254.
28. Zadeh G and Guha A (2003). Neoangiogenesis in human astrocytomas: expression and functional role of angiopoietins and their cognate receptors. Front Biosci 8, e128-e137.
29. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, and Holash J (2000). Vascular-specific growth factors and blood vessel formation. Nature 407, 242-248.
30. Oshima Y, Oshima S, Nambu H, Kachi S, Takahashi K, Umeda N, Shen J, Dong A, Apte RS, Duh E, et al. (2005). Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive. FASEB J 19, 963-965.